Chief Executive Officer
Ed Seguine brings more than 20 years of experience as a clinical technology executive at big pharma and startup organizations to the Clinical ink team. He joined Clinical ink in 2012 with the goal of creating a company that would eliminate problems caused by current paper-based processes and technologies. Prior to joining Clinical ink, he served as general manager, trial planning at Medidata Solutions, where he managed acquisition integration activities and product positioning prior to the company’s IPO. Prior, Ed was a founding manager of the Eli Lilly & Co. venture capital funds, e.Lilly, and Lilly Bioventures, focusing on technology and biotech and device companies.
Areas of Expertise
- Clinical trial business model innovation
- Clinical development process optimization and technology adoption
- Private equity, venture capital
- Patient data collection in clinical trials (ePRO/eCOA/eSource/virtual)